Author Interviews, Cancer Research / 17.12.2025
Icahn Mount Sinai Scientists Engineer mRNA to Selectively Target Cancer Cells
[caption id="attachment_71812" align="alignleft" width="200"]
Dr. Zak[/caption]
MedicalResearch.com Interview with:
Magdalena M. Żak, PhD
Zangi Lab
Instructor | Cardiovascular Research Institute
Instructor | Genetics & Genomic Sciences
Icahn School of Medicine at Mount Sinai
Hess Center for Science and Medicine
New York, NY 10029
MedicalResearch.com: What is the background for this study?
Response: mRNA has proven to be a groundbreaking technology through COVID-19 vaccines, and most mRNA-based therapeutics in development today are still focused on vaccines. However, in principle, mRNA could be used for many diseases in which expression of a therapeutic protein would be beneficial. A major reason mRNA is less commonly used outside of vaccines is the lack of robust targeting: for vaccination, broad expression can be acceptable because the goal is antigen production for immune recognition, but for other applications - especially cancer - targeted delivery and minimized off-target expression are critical to reduce side effects. Current targeting strategies largely rely on lipid nanoparticles (LNPs), which act as lipid “carriers” for systemic delivery. Although LNPs can be designed to show some tissue tropism, this is often limited to organs such as the liver, spleen, and lungs.
Dr. Zak[/caption]
MedicalResearch.com Interview with:
Magdalena M. Żak, PhD
Zangi Lab
Instructor | Cardiovascular Research Institute
Instructor | Genetics & Genomic Sciences
Icahn School of Medicine at Mount Sinai
Hess Center for Science and Medicine
New York, NY 10029
MedicalResearch.com: What is the background for this study?
Response: mRNA has proven to be a groundbreaking technology through COVID-19 vaccines, and most mRNA-based therapeutics in development today are still focused on vaccines. However, in principle, mRNA could be used for many diseases in which expression of a therapeutic protein would be beneficial. A major reason mRNA is less commonly used outside of vaccines is the lack of robust targeting: for vaccination, broad expression can be acceptable because the goal is antigen production for immune recognition, but for other applications - especially cancer - targeted delivery and minimized off-target expression are critical to reduce side effects. Current targeting strategies largely rely on lipid nanoparticles (LNPs), which act as lipid “carriers” for systemic delivery. Although LNPs can be designed to show some tissue tropism, this is often limited to organs such as the liver, spleen, and lungs.
Prof. Michaelides[/caption]
Professor Michel Michaelides BSc MB BS MD(Res) FRCOphth FACS
Professor of Ophthalmology and Consultant Ophthalmic Surgeon
UCL Institute of Ophthalmology and Moorfields Eye Hospital
MedicalResearch.com: What is the background for this study?
Valentina Paz[/caption]
Valentina Paz, M.Sc
Prof. Rahi[/caption]
Prof. Jugnoo S Rahi
Professor of Ophthalmic Epidemiology and Honorary Consultant Ophthalmologist
NIHR Senior Investigator
Head,
Prof Jeffrey S Tobias, Prof Jayant S Vaidya, Prof Max Bulsara and Prof Michael BaumMedicalResearch.com Interview with:[/caption]
Professor Jayant S Vaidya
MBBS MS DNB FRCS PhD
Professor of Surgery and Oncology
University College London
MedicalResearch.com: What is the background for this study? What type of single dose radiation is used?
Response: The new paper published in the British Journal of Cancer (
Dr Sarah Myers PhD
Honorary Research Associate
UCL Department of Anthropology
MedicalResearch.com: What is the background for this study?
Response: Postnatal or postpartum depression is unfortunately common after giving birth; a figure often quoted is 15%, but some studies have found much higher numbers. Postnatal depression is associated with a range of poorer outcomes for mothers and their infants, and the financial costs of treating maternal mental ill health put health services under considerable strain. Studies have found that providing additional emotional support to at risk mothers, for instance via peer support programmes or regular phone calls with health visitors, can reduce the likelihood of them developing the condition. Therefore, it is really important that we understand the full range of risk factors that put women at greater risk of becoming depressed after giving birth.
There is increasing evidence for a link between inflammation and depression, with factors that trigger an inflammatory immune response also increasing the likelihood of depressive symptoms. The opens up the possibility of finding new risk factors for postnatal depression based on known associations with inflammation.